CompaniesDay One Biopharmaceuticals
Day One Biopharmaceuticals logo

Day One Biopharmaceuticals

active
Brisbane, CA, United States
Founded 2018
Website
About

Cancer Treatments

Areas of Focus

Categories

Small Molecule PharmaceuticalBiotech
Team (17)
Adam Dubow
Adam Dubow
Adam Dubow
Day One Biopharmaceuticals
team_member
Charles N
Charles N
Charles N. York II, MBA
Day One Biopharmaceuticals
team_member
Davy Chiodin
Davy Chiodin
Davy Chiodin, PharmD
Day One Biopharmaceuticals
team_member
Elly Barry
Elly Barry
Elly Barry, MD
Day One Biopharmaceuticals
team_member
Garry Nicholson
Garry Nicholson
Garry Nicholson, MBA
Day One Biopharmaceuticals
team_member
Habib Dable
Habib Dable
Habib Dable
Day One Biopharmaceuticals
team_member
View all 17 team members →
Clinical Trials (8)
View all

Total Trials

8

As Lead Sponsor

6

As Collaborator

2

Total Enrollment

963

By Phase

PHASE1: 3PHASE3: 1PHASE2: 3

By Status

RECRUITING: 4TERMINATED: 2ACTIVE_NOT_RECRUITING: 1APPROVED_FOR_MARKETING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
NCT03429803
NCT04775485
NCT04985604
NCT07121829
NCT05465174
NCT05566795
NCT06752681
Hover over trial bars to see details

Recent Trials

NCT06752681Lead Sponsor
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
PHASE1Recruiting
254 participants
Started: Nov 18, 2024 · Completed: Dec 31, 2028
NCT05566795Lead Sponsor
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
PHASE3Recruiting
400 participants
Started: Feb 27, 2023 · Completed: Mar 31, 2030
NCT05465174Collaborator
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
PHASE2Recruiting
57 participants
Started: Sep 12, 2022 · Completed: Mar 1, 2028
NCT07121829Lead Sponsor
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
PHASE1Terminated
44 participants
Started: May 2, 2022 · Completed: Dec 18, 2024
NCT04985604Lead Sponsor
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
PHASE2Terminated
23 participants
Started: Jul 15, 2021 · Completed: Jul 8, 2024
View all 8 trials →
Funding History (20)
8-K
Oct 10, 2025
Filing
8-K
Aug 5, 2025
Filing
8-K
Jun 3, 2025
Filing
8-K
May 6, 2025
Filing
DEFA14A
Apr 11, 2025
Filing
DEF 14A
Apr 11, 2025
Filing
8-K
Feb 25, 2025
Filing
8-K
Jan 13, 2025
Filing
8-K
Nov 20, 2024
Filing
8-K
Oct 30, 2024
Filing
Locations (1)
Headquarters
Brisbane, CA, United States
Map

Loading map...